论文部分内容阅读
以人ａ－干扰素（ＩＦＮ－ａ）基因为治疗性目的基因，建立了ＩＦＮ－ａ基因疗法治疗人黑色素瘤的实验模型并探讨其免疫学机理。方法将人ＩＦＮ－ａ基因体外转染成纤维细胞ＮＩＨ３Ｔ３中，获得一株高分泌ＩＦＮ－ａ的细胞克隆株ＮＩＨ３Ｔ３－ＩＦＮ－ａ＋。将该高分泌ＩＦＮ－ａ细胞克隆株在体外大量扩增后回植裸鼠腹腔内，测定裸鼠血清中ＩＦＮ－ａ的含量并观察对荷瘤裸鼠的治疗效果。结果 １２ｈ后裸鼠血清中即能测到ＩＦＮ－ａ活性并能维持较长时间，荷瘤裸鼠的存活期明显延长。结论 经成纤维细胞途径能成功地将人ＩＦＮ－ａ基因导入体内并有效表达，同时对荷黑色素瘤裸鼠的肿瘤生长有明显的抑制作用，为临床应用ＩＦＮ－ａ基因疗法治疗黑色素瘤提供实验依据并建立新的应用方法。
A human interferon-alpha (IFN-a) gene was used as a therapeutic target gene to establish an experimental model of IFN-a gene therapy for human melanoma and to explore its immunological mechanism. Methods Human IFN-a gene was transfected into NIH3T3 fibroblasts in vitro to obtain a cell clone NIH3T3-IFN-a + secreting IFN-a. The large number of IFN-a secreting cell clone was amplified in vitro and transplanted into the peritoneal cavity of nude mice. The content of IFN-a in nude mice was measured and the therapeutic effect on nude mice bearing tumor was observed. The results of 12h after nude mice serum IFN-a activity can be measured and can be maintained for a long time, tumor-bearing nude mice significantly prolonged survival. Conclusions The human IFN-a gene can be successfully introduced into human body through fibroblast pathway and expressed effectively, meanwhile, it can significantly inhibit tumor growth in melanoma-bearing nude mice and provide experiment for clinical application of IFN-α gene therapy for melanoma Based on and establish new application method.